SCHEMBL1010612

SCHEMBL1010612

CC(C)(Oc1cccc(CCCNCC(Oc2ccccc2)c2nc3ccccc3o2)c1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 14/20 0.56
PPARG P37231 13/20 0.56
PPARD Q03181 9/20 0.56
ADRB3 P13945 3/20 0.40
CYP4F2 P78329 2/20 0.39
CYP4A11 Q02928 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1009685 0.95 PPARG (0.54) PPARAPPARGPPARDADRB3
SCHEMBL1010742 0.92 PPARG (0.51) PPARAPPARGPPARDADRB3
SCHEMBL1009638 0.90 PPARG (0.50) PPARAPPARGPPARDADRB3
SCHEMBL1009837 0.90 PPARA (0.52) PPARAPPARGPPARD
SCHEMBL1009876 0.86 ADRB3 (0.56) PPARAPPARGPPARDADRB3
SCHEMBL1010640 0.86 PPARG (0.40) PPARAPPARGPPARDADRB3
SCHEMBL1009987 0.85 PPARA (0.48) PPARAPPARGPPARD
SCHEMBL6544050 0.85 PPARG (0.56) PPARAPPARGPPARDADRB3CYP4F2
SCHEMBL1009457 0.85 PPARA (0.51) PPARAPPARGPPARD
SCHEMBL6544252 0.83 PPARG (0.62) PPARAPPARGPPARDCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661890-B1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOWA CO (JP) 2011-01-05 EP disclosed
US-7183295-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2007-02-27 US disclosed
US-7109226-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-09-19 US disclosed
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-08-24 US disclosed
EP-1661890-A1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kowa Co., Ltd. (JP) 2006-05-31 EP disclosed
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARA, PPARG, PPARD PPARA 1/4885PPARG 2/4885PPARD 3/4885
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.